Alloantigen recognition is critical for CD8 T cell-mediated graft anti-tumor activity against murine BCL1 lymphoma after myeloablative bone marrow transplantation

Asha Pillai, P. Teo, T. George, A. Mukhopadhyay, S. Dejbakhsh-Jones, S. Strober

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The goal of the current study was to determine whether whole bone marrow cells or splenic CD8+ T cells from C57BL/6 (H-2b) donor mice, which are tolerant to BALB/c (H-2d) alloantigens, are capable of mediating graft anti-tumor activity against a BALB/c B-cell lymphoma after injection into irradiated BALB/c hosts. The experimental results show that high doses of splenic CD8+ T cells mixed with T cell-depleted bone marrow cells from C57BL/6 non-tolerant (normal) donors eliminate the BCL1 B-cell lymphoma cells and induce lethal graft-versus-host disease (GVHD). CD8+ T cells from tolerant donors simultaneously lose both their ability to induce GVHD and their anti-tumor activity. Whole bone marrow cell transplants from normal donors eliminated BCL1 tumor cells without inducing GVHD, and bone marrow cells from tolerant donors failed to eliminate the tumor cells. The infused BCL1 tumor cells expressed an immunogenic tumor-specific idiotype antigen disparate from host alloantigens, indicating that recognition of the tumor-specific antigen alone was insufficient to elicit graft anti-tumor activity from unimmunized allotolerant donor splenic CD8+ T cells or whole bone marrow cells. We conclude that CD8+ T cells from unimmunized normal donor mice require alloantigen recognition to mediate their anti-tumor activity following allogeneic BMT.

Original languageEnglish (US)
Pages (from-to)487-497
Number of pages11
JournalBone Marrow Transplantation
Volume40
Issue number5
DOIs
StatePublished - Sep 1 2007
Externally publishedYes

Fingerprint

Isoantigens
Bone Marrow Transplantation
Lymphoma
T-Lymphocytes
Transplants
Bone Marrow Cells
Neoplasms
Graft vs Host Disease
B-Cell Lymphoma
Neoplasm Antigens
Antigens
Injections

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Alloantigen recognition is critical for CD8 T cell-mediated graft anti-tumor activity against murine BCL1 lymphoma after myeloablative bone marrow transplantation. / Pillai, Asha; Teo, P.; George, T.; Mukhopadhyay, A.; Dejbakhsh-Jones, S.; Strober, S.

In: Bone Marrow Transplantation, Vol. 40, No. 5, 01.09.2007, p. 487-497.

Research output: Contribution to journalArticle

@article{23de05ce19384b048b8217e3e4db1d37,
title = "Alloantigen recognition is critical for CD8 T cell-mediated graft anti-tumor activity against murine BCL1 lymphoma after myeloablative bone marrow transplantation",
abstract = "The goal of the current study was to determine whether whole bone marrow cells or splenic CD8+ T cells from C57BL/6 (H-2b) donor mice, which are tolerant to BALB/c (H-2d) alloantigens, are capable of mediating graft anti-tumor activity against a BALB/c B-cell lymphoma after injection into irradiated BALB/c hosts. The experimental results show that high doses of splenic CD8+ T cells mixed with T cell-depleted bone marrow cells from C57BL/6 non-tolerant (normal) donors eliminate the BCL1 B-cell lymphoma cells and induce lethal graft-versus-host disease (GVHD). CD8+ T cells from tolerant donors simultaneously lose both their ability to induce GVHD and their anti-tumor activity. Whole bone marrow cell transplants from normal donors eliminated BCL1 tumor cells without inducing GVHD, and bone marrow cells from tolerant donors failed to eliminate the tumor cells. The infused BCL1 tumor cells expressed an immunogenic tumor-specific idiotype antigen disparate from host alloantigens, indicating that recognition of the tumor-specific antigen alone was insufficient to elicit graft anti-tumor activity from unimmunized allotolerant donor splenic CD8+ T cells or whole bone marrow cells. We conclude that CD8+ T cells from unimmunized normal donor mice require alloantigen recognition to mediate their anti-tumor activity following allogeneic BMT.",
author = "Asha Pillai and P. Teo and T. George and A. Mukhopadhyay and S. Dejbakhsh-Jones and S. Strober",
year = "2007",
month = "9",
day = "1",
doi = "10.1038/sj.bmt.1705759",
language = "English (US)",
volume = "40",
pages = "487--497",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Alloantigen recognition is critical for CD8 T cell-mediated graft anti-tumor activity against murine BCL1 lymphoma after myeloablative bone marrow transplantation

AU - Pillai, Asha

AU - Teo, P.

AU - George, T.

AU - Mukhopadhyay, A.

AU - Dejbakhsh-Jones, S.

AU - Strober, S.

PY - 2007/9/1

Y1 - 2007/9/1

N2 - The goal of the current study was to determine whether whole bone marrow cells or splenic CD8+ T cells from C57BL/6 (H-2b) donor mice, which are tolerant to BALB/c (H-2d) alloantigens, are capable of mediating graft anti-tumor activity against a BALB/c B-cell lymphoma after injection into irradiated BALB/c hosts. The experimental results show that high doses of splenic CD8+ T cells mixed with T cell-depleted bone marrow cells from C57BL/6 non-tolerant (normal) donors eliminate the BCL1 B-cell lymphoma cells and induce lethal graft-versus-host disease (GVHD). CD8+ T cells from tolerant donors simultaneously lose both their ability to induce GVHD and their anti-tumor activity. Whole bone marrow cell transplants from normal donors eliminated BCL1 tumor cells without inducing GVHD, and bone marrow cells from tolerant donors failed to eliminate the tumor cells. The infused BCL1 tumor cells expressed an immunogenic tumor-specific idiotype antigen disparate from host alloantigens, indicating that recognition of the tumor-specific antigen alone was insufficient to elicit graft anti-tumor activity from unimmunized allotolerant donor splenic CD8+ T cells or whole bone marrow cells. We conclude that CD8+ T cells from unimmunized normal donor mice require alloantigen recognition to mediate their anti-tumor activity following allogeneic BMT.

AB - The goal of the current study was to determine whether whole bone marrow cells or splenic CD8+ T cells from C57BL/6 (H-2b) donor mice, which are tolerant to BALB/c (H-2d) alloantigens, are capable of mediating graft anti-tumor activity against a BALB/c B-cell lymphoma after injection into irradiated BALB/c hosts. The experimental results show that high doses of splenic CD8+ T cells mixed with T cell-depleted bone marrow cells from C57BL/6 non-tolerant (normal) donors eliminate the BCL1 B-cell lymphoma cells and induce lethal graft-versus-host disease (GVHD). CD8+ T cells from tolerant donors simultaneously lose both their ability to induce GVHD and their anti-tumor activity. Whole bone marrow cell transplants from normal donors eliminated BCL1 tumor cells without inducing GVHD, and bone marrow cells from tolerant donors failed to eliminate the tumor cells. The infused BCL1 tumor cells expressed an immunogenic tumor-specific idiotype antigen disparate from host alloantigens, indicating that recognition of the tumor-specific antigen alone was insufficient to elicit graft anti-tumor activity from unimmunized allotolerant donor splenic CD8+ T cells or whole bone marrow cells. We conclude that CD8+ T cells from unimmunized normal donor mice require alloantigen recognition to mediate their anti-tumor activity following allogeneic BMT.

UR - http://www.scopus.com/inward/record.url?scp=34548072873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548072873&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1705759

DO - 10.1038/sj.bmt.1705759

M3 - Article

C2 - 17603512

AN - SCOPUS:34548072873

VL - 40

SP - 487

EP - 497

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 5

ER -